NCT03682419

Brief Summary

Comparison of capillary whole blood INR determined by LumiraDx Instrument to venous plasma INR determined by laboratory reference method (IL ACL ELITE PRO) for method comparison and assessment of accuracy and bias by regression analysis and other analytical methods.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
420

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Sep 2018

Shorter than P25 for not_applicable

Geographic Reach
1 country

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 17, 2018

Completed
2 days until next milestone

First Submitted

Initial submission to the registry

September 19, 2018

Completed
5 days until next milestone

First Posted

Study publicly available on registry

September 24, 2018

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 23, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 23, 2018

Completed
Last Updated

February 27, 2019

Status Verified

September 1, 2018

Enrollment Period

2 months

First QC Date

September 19, 2018

Last Update Submit

February 26, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • To determine the clinical performance of the LumiraDx instrument

    Measurement of INR using Capillary \& Venous blood samples

    8 weeks

Secondary Outcomes (1)

  • To determine the accuracy of the LumiraDx instrument

    8 weeks

Study Arms (2)

VKA Patients

EXPERIMENTAL

Single Arm - blood collection by venepuncture and fingerstick in patients undergoing Warfarin Therapy

Procedure: VKA PatientsProcedure: Non-VKA Patients

non-Vka Patients

EXPERIMENTAL

Single Arm - blood collection by venepuncture and fingerstick in patients not undergoing Warfarin Therapy

Procedure: VKA PatientsProcedure: Non-VKA Patients

Interventions

VKA PatientsPROCEDURE

Venepuncture and capillary blood collection from Patients receiving Warfarin Therapy

Also known as: Fingerstick to collect blood samples from Patients, Venepuncture to collect blood samples from Patients
VKA Patientsnon-Vka Patients

Venepuncture and capillary blood collection from Patients not receiving Warfarin Therapy

Also known as: Fingerstick to collect blood samples from Patients, Venepuncture to collect blood samples from Patients
VKA Patientsnon-Vka Patients

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Persons \>18 years of age
  • Willing and able to provide written informed consent and comply with study procedures
  • Currently prescribed vitamin K antagonist therapy
  • Deemed medically appropriate for study participation by the Investigator

You may not qualify if:

  • Persons \<18 years of age
  • Subject has previously participated in this study
  • Subject is within 4 weeks of first prescription of vitamin K antagonist therapy
  • Confirmed or suspected pregnancy
  • Unwilling or unable to provide written informed consent and comply with study procedures
  • Vulnerable populations deemed inappropriate for study by the Investigator
  • Deemed medically inappropriate for study by the Investigator (i.e. patients with a known inherited \[e.g. haemophilia or von Willebrand's disease\] or acquired \[e.g. liver cirrhosis\] condition likely to be associated with a coagulopathy; or patients receiving non-VKA anticoagulant medications)
  • Persons \>18 years of age
  • Willing and able to provide written informed consent and comply with study procedures
  • Deemed medically appropriate for study participation by the Investigator
  • Persons \<18 years of age
  • Subject has previously participated in this study
  • Confirmed or suspected pregnancy
  • Unwilling or unable to provide written informed consent and comply with study procedures
  • Vulnerable populations deemed inappropriate for study by the Investigator
  • +1 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Glasgow Royal Infirmary Clinical Research Facility

Glasgow, G4 0SF, United Kingdom

Location

Golden Jubilee National Hospital

Glasgow, G81 4DY, United Kingdom

Location

Wishaw General Hospital, NHS Lanarkshire

Wishaw, ML2 0DP, United Kingdom

Location

Related Publications (1)

  • Tait RC, Hung A, Gardner RS. Performance of the LumiraDx Platform INR Test in an Anticoagulation Clinic Point-of-Care Setting Compared With an Established Laboratory Reference Method. Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619890423. doi: 10.1177/1076029619890423.

MeSH Terms

Conditions

Venous ThrombosisAtrial FibrillationDonath-Landsteiner hemolytic anemiaPulmonary EmbolismThrombophiliaAntiphospholipid Syndrome

Condition Hierarchy (Ancestors)

ThrombosisEmbolism and ThrombosisVascular DiseasesCardiovascular DiseasesArrhythmias, CardiacHeart DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsLung DiseasesRespiratory Tract DiseasesEmbolismHematologic DiseasesHemic and Lymphatic DiseasesAutoimmune DiseasesImmune System Diseases

Study Officials

  • Robert C Tait, BSc (Hons)

    Consultant Haematologist

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Model Details: A performance evaluation study.
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 19, 2018

First Posted

September 24, 2018

Study Start

September 17, 2018

Primary Completion

November 23, 2018

Study Completion

November 23, 2018

Last Updated

February 27, 2019

Record last verified: 2018-09

Data Sharing

IPD Sharing
Will not share

Locations